Compare WEN & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WEN | LTGO |
|---|---|---|
| Founded | 1969 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2000 | 2026 |
| Metric | WEN | LTGO |
|---|---|---|
| Price | $9.01 | $22.37 |
| Analyst Decision | Hold | |
| Analyst Count | 22 | 0 |
| Target Price | ★ $8.84 | N/A |
| AVG Volume (30 Days) | ★ 9.7M | 385.4K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $2,176,891,000.00 | N/A |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | $0.94 | N/A |
| P/E Ratio | $30.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.07 | $17.22 |
| 52 Week High | $10.62 | $21.71 |
| Indicator | WEN | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 64.30 | 85.35 |
| Support Level | $7.84 | $18.46 |
| Resistance Level | $9.45 | N/A |
| Average True Range (ATR) | 0.41 | 1.31 |
| MACD | 0.12 | 0.35 |
| Stochastic Oscillator | 98.98 | 96.70 |
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.